Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Jessica Skarzynski
The addition of the investigational drug alisertib to a paclitaxel regimen showed promising activity in patients with recurrent ovarian cancer or advanced breast cancer.
Kristie L. Kahl
A recent survey demonstrated the common tradeoffs most patients report regarding treatment decisions, highlighting the importance of shared decision making.
Kelly Irvin
Rather than revisiting the ghosts of cancer treatments past, I’m focused on using what I’ve learned in three years of active treatment and maintenance for incurable, metastatic cancer.
Jessica Skarzynski
Here are the top 5 CURE stories for December 2018.
Brielle Benyon
This is the first approval of a PARP inhibitor as a first-line maintenance treatment for BRCA-mutant gynecologic cancers.
Brielle Benyon
The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.
Katie Kosko
A new program offers counseling, patient education and vetted referrals to patients and their families.
Jessica Skarzynski
Maintenance treatment with Lynparza (olaparib) after chemotherapy has been found to significantly extend progression-free survival in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation, according to a recent phase 3 study.
Shannon Pulaski
A cancer diagnosis can lead to discussions about family health history, as well as a whole new world to learn about.
Maurie Markman, M.D.
Patients with ovarian cancer are living longer than ever.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other